Human Genome Sciences HGSI BENLYSTA News

September 4, 2009 - Shares of Human Genome Sciences, Inc. (HGSI) could get a lift today on the following news:

Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in serologically active patients with SLE. This primary endpoint was accepted by the FDA under a Special Protocol Assessment agreement for the Phase 3 trials.

In July 2009, HGS and GSK announced that belimumab met this primary endpoint in BLISS-52, the first of the two Phase 3 trials. Results from BLISS-76, the second Phase 3 trial, are expected in November 2009. Belimumab is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Full Article - Click Here

Looking at the charts, HGSI stock needs to get back above the 10 day moving average at $18.60. If HGSI does close back above the 10 day, $20 is the next resistance level. HGSI has been falling ever since the Immunomedics Inc. (IMMU) news was released.


For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free